Search

everythinglearnresearchcommunity

for

Search:↓

Nanocarrier-based treatments show promise for better hair growth in androgenetic alopecia but need more research.

Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.

Developing microRNA-based treatments is hard but has potential.

Light-based treatment, Photobiomodulation, shows promise for non-invasive skin therapy with few side effects.

The supplement with Serenoa repens and Pygeum africanum significantly increased active hair growth and decreased rest phase hair in post-menopausal women with hair loss, with only mild digestive side effects.

Blocking RANK signaling might help treat metastatic melanoma, but more research is needed.

Finasteride effectively treats BPH and hair loss but may cause sexual side effects.

Dermatologists should carefully manage hair loss in cancer patients to improve their quality of life.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

Leontopodium alpinum extract may help reduce hair shedding by keeping hair in the growth phase longer.

STAT5 activation is crucial for starting the hair growth phase.

Quick, selective detection of tadalafil and finasteride in human plasma developed.

Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Photobiomodulation therapy significantly increases hair density and growth for androgenic alopecia, but more research is needed to confirm safety.

Testosterone therapy is generally safe for transmen, improves sexual function, and has manageable health risks with proper monitoring.

Extended-release divalproex is better tolerated and more effective for seizures and psychiatric symptoms than delayed-release divalproex, but doesn't reduce hair loss.

The document concludes that it's important to understand the placebo effect when evaluating the effectiveness of treatments in medical trials.

Hidradenitis suppurativa is a chronic skin condition more common in women, linked to genetics and lifestyle factors, and associated with various other health issues.

The conclusion is that maintaining blinding in clinical trials is crucial for reliable results.

The conclusion suggests that the zinc lozenge study is valid despite imperfect blinding, as many participants could not correctly identify their lozenge type.

Sabal and Urtica extract works as well as finasteride for treating BPH, with fewer side effects.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Polyphenols may help treat skin conditions like warts, hair loss, acne, and dark spots, but more research is needed.

Case-only trees and random forests improve predictions of treatment effects in clinical trials.

Dutasteride more effective than finasteride for hair growth; SM04554 safe and potentially effective for hair loss.

Bee pollen, green tea, essential oils, and various plant extracts improve skin and hair health.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

The PCOS-specific questionnaire needs more work to fully measure quality of life in clinical trials.